| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.37▼ | 4.37▼ | 4.39▼ | 4.30▼ | 4.10▲ |
| MA10 | 4.41▼ | 4.40▼ | 4.38▼ | 4.34▼ | 3.69▲ |
| MA20 | 4.37▼ | 4.33▼ | 4.36▼ | 3.97▲ | 2.55▲ |
| MA50 | 4.42▼ | 4.53▼ | 4.55▼ | 3.31▲ | 2.08▲ |
| MA100 | 4.61▼ | 4.25▲ | 4.05▲ | 2.27▲ | 2.30▲ |
| MA200 | 4.52▼ | 3.61▲ | 2.99▲ | 1.98▲ | 5.24▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.007▼ | 0.004▲ | 0.001▲ | -0.041▼ | 0.218▲ |
| RSI | 40.828▼ | 43.947▼ | 45.751▼ | 54.285▲ | 62.648▲ |
| STOCH | 38.095 | 43.675 | 65.763 | 28.783 | 60.799 |
| WILL %R | -100.000▼ | -62.295 | -54.286 | -59.459 | -36.147 |
| CCI | -193.954▼ | -63.853 | -25.380 | -31.419 | 75.752 |
|
Tuesday, February 18, 2025 08:26 PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has reported positive Phase 2 trial results for ATH434, its lead candidate for Multiple System Atrophy (MSA), a rare and progressive Parkinsonian ...
|
|
Monday, February 10, 2025 04:32 AM
Alterity Therapeutics (ATHE) has received binding commitments for a capital raising of A$40M via a two tranche placement of fully paid ordinary ...
|
|
Monday, February 10, 2025 04:25 AM
Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 18/02/25 | 4.42 | 4.42 | 4.10 | 4.11 | 24,727 |
| 14/02/25 | 4.38 | 4.50 | 4.28 | 4.42 | 58,880 |
| 13/02/25 | 4.02 | 4.52 | 4.02 | 4.42 | 58,515 |
| 12/02/25 | 4.31 | 4.31 | 4.06 | 4.20 | 52,850 |
| 11/02/25 | 4.49 | 4.50 | 4.30 | 4.34 | 49,950 |
| 10/02/25 | 4.45 | 4.72 | 4.252 | 4.62 | 199,979 |
| 07/02/25 | 4.25 | 4.25 | 4.25 | 4.25 | 0 |
| 06/02/25 | 4.25 | 4.25 | 4.25 | 4.25 | 0 |
| 05/02/25 | 4.51 | 4.51 | 4.14 | 4.25 | 193,482 |
| 04/02/25 | 5.10 | 5.10 | 4.51 | 4.51 | 135,123 |
|
|
||||
|
|
||||
|
|